## MRK: Merck & Co., Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($101.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Where is Merck & Co. (MRK) Headed According to Wall Street?**
- Source: Finviz | 20251230T051308 | Bullish | Relevance: 100%
- Merck & Co., Inc. (MRK) has been reaffirmed a Buy rating by Jefferies analyst Tycho Peterson with a $139.00 price target after the company announced a historic agreement with the Trump administration aimed at making its medicines more affordable and accessible. This agreement includes a direct-to-patient program offering significant discounts on key products and a three-year delay on Section 232 tariffs, allowing for U.S. manufacturing investments. The company, a biopharmaceutical entity, focuses on delivering health solutions through its Pharmaceutical and Animal Health segments.

**2. Merck (MRK) Stock Today: Latest News, Analyst Forecasts, and What Investors Should Watch Before Mondayâ€™s Open**
- Source: ts2.tech | 20251228T190835 | Bullish | Relevance: 100%
- Merck & Co., Inc. (NYSE: MRK) shares are approaching new highs as the year ends, fueled by a positive shift in analyst sentiment, including an upgrade from BMO Capital Markets. Investors are watching for the stock's performance this coming week, especially its ability to hold recent breakout levels in a low-liquidity market. Upcoming catalysts include the February 3, 2026 Q4 earnings call, which will provide more clarity on Merck's growth strategy beyond Keytruda.

**3. Fort Washington Investment Advisors Inc. OH Has $51.42 Million Stock Position in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251230T120021 | Somewhat-Bullish | Relevance: 100%
- Fort Washington Investment Advisors Inc. OH increased its stake in Merck & Co., Inc. by 13.4% in the third quarter, now holding 612,688 shares valued at approximately $51.42 million. Merck recently boosted its quarterly dividend to $0.85 per share, representing an annualized payout of $3.40 and a 3.2% yield. The company currently holds a consensus "Hold" rating from analysts with an average price target of $110.13.

**4. Diversified Trust Co Purchases 18,187 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251230T101437 | Bullish | Relevance: 100%
- Diversified Trust Co increased its stake in Merck & Co., Inc. by 9.6% in the third quarter, acquiring an additional 18,187 shares and bringing its total holdings to 207,838 shares valued at approximately $17.44 million. Merck also announced a quarterly dividend increase to $0.85 per share, resulting in a 3.2% yield. The company currently holds a "Hold" consensus rating from analysts with a target price of $110.13.

**5. Farmers & Merchants Investments Inc. Cuts Stock Position in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251230T100809 | Neutral | Relevance: 100%
- Farmers & Merchants Investments Inc. reduced its stake in Merck & Co., Inc. by 9.2% in Q3, selling 12,500 shares, bringing its total holding to 123,142 shares valued at approximately $10.34 million. Merck increased its quarterly dividend to $0.85 per share, resulting in an annualized dividend of $3.40 and a yield of about 3.2%. Analyst sentiment on Merck is mixed, with a consensus "Hold" rating and an average price target of $110.13, while the stock currently trades around $106.47.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | BMO Capital | $130 | $82 | +59% |
| 2025-12-15 | B of A Securiti | $120 | $105 | +14% |
| 2025-12-12 | Morgan Stanley | $102 | $100 | +2% |
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | BMO Capital | up | Outperform |
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-04 | Scotiabank | main | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +24%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (5 raises, avg +24%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $264.9B |
| Beta | 0.30 |
| 52W Range | $73.31 - $107.59 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 12.8 |
| Current P/E | 11.8 |
| YoY Growth | -7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.3% to 2.1% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.10% (CS: 95) | Neutral |
| RSI_14 | 67.9 | Neutral |
| MACD Histogram | 0.30 | Bullish |
| vs SMA20 | 1.044x | Above |
| vs SMA50 | 1.111x | Above |
| vs SMA200 | 1.240x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $106.09
- **Stop Loss:** $101.55 (4.3% risk)
- **Target:** $110.63 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 290
- **Position Value:** $30,766.10
- **Portfolio %:** 30.77%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*